At the 2019 ASCO Annual Meeting in Chicago, US, Tapan M. Kadia from MD Anderson Cancer Center, Houston, US, discusses the current challenges facing AML treatment.
Dr. Kadia discusses the significant improvement in many of the current therapies, with the discovery and recent approval of drugs such as venetoclax and IDH1 and IDH2 inhibitors as well as new FLT3 inhibitors, however, there are several challenges that still remain. Dr. Kadia explains that some of the biggest challenges that still remain are the ones that occur when patients have secondary AML, prior myeloblastic syndrome or aplastic anemia, which have then transformed into acute myeloid leukemia.